LONG-TERM TREATMENT WITH LISINOPRIL AND CARVEDILOL IN PATIENTS WITH UNSTABLE ANGINA AT REST

Download full text PDF
Issue: 
3
Year: 
2016

Professor A. Strutynsky, MD; A. Kallaeva, MD; P. Gazieva; Professor A. Baranov, MD; V. Trishina, Candidate of Medical Sciences; Yu. Golubev, Candidate of Medical Sciences; G. Golubeva, Candidate of Medical Sciences N.I. Pirogov Russian National Research Medical University, Moscow

The efficiency of long-term outpatient treatment with the angiotensin-converting enzyme inhibitor Lisinopril and the vasodilatory α1-, β1, 2-adrenoblocker carvedilol was studied in patients with coronary heart disease and hypertension who had experienced severe attacks of unstable angina at rest. It was shown that this treatment might substantially slow down the process of ischemic remodeling of the left ventricle (LV), favors regression of its hypertrophy, its better diastolic and systolic function, a lower risk for poor coronary events and progressive chronic heart failure, two-year mortality and ventricular and supraventricular arrhythmia rates.
Keywords: 
cardiology
carvedilol
Lisinopril
unstable angina
ischemic remodeling

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Natsional'nye rekomendatsii po lecheniju ostrogo koronarnogo sindro ma bez stojkogo pod'ema ST na EKG // Kardiovask. ter. i profilakt. – 2006; 5 (Pril. 1): 411–40.
  2. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation // Eur. Heart J. – 2011; 33: 2999–3034.
  3. Kallaeva A.N. Osobennosti remodelirovanija levogo zheludochka, bli zhajshego i otdalennogo prognoza u bol'nyh, perenesshih infarkt miokarda bez zubtsa Q ili nestabil'nuju stenokardiju. Avtoref. dis. … d-ra med. nauk. M., 2005.
  4. Agmadova Z.M., Kallaeva A.N. Osobennosti progressirovanija remode lirovanija miokarda u bol'nyh s razlichnymi formami nestabil'noj steno-kardii // Kardiologija. – 2014; 7: 9–16.
  5. Conti C. Risk stratification in unstable angina: how to select patients who need emergency revascularization // J. Card. Surg. – 1993; 8 (3): 391–5.
  6. Hamm C., Braunwald E. Slassification of unstable angina revisited // Circulation. – 2000; 102: 118–22.
  7. Bugiardini R., Pozzati A., Borghi A. et al. Angiographic morphology in unstable angina and its relation to transient myocardial ischemia and hospital outcome // Am. J. Cardiol. – 1991; 67 (6): 460–4.
  8. Zakirova A.N., Oganov R.G., Zakirova N.E i dr. Remodelirovanie mio karda pri ishemicheskoj bolezni serdtsa // Rats. farmakoter. v kardiol. – 2009; 1: 42–5.
  9. Buziashvili Ju.I., Kljuchnikov I.V., Melkonjan A.M. i dr. Ishemicheskoe remodelirovanie levogo zheludochka (opredelenie, patogenez, diagnostika, medikamentoznaja i hirurgicheskaja korrektsija) // Kardiologija. – 2002; 10: 88–94.
  10. Braunwald E., Antman E., Beasley J. et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology. American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Unstable Angina) // J Am Coll Cardiol. – 2000; 36: 970–1062.
  11. Rojtberg G.E., Strutynskij A.V. Vnutrennie bolezni. Serdechno sosudistaja sistema / M.: MEDpress-inform, 2011; 895 s.
  12. Packer M., Bristow M., Cohn J. et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: US Carvedilol Heart Failure Study Group (see comments) // N. Engl. J. Med. – 1996; 334: 1349–55. Comment. 1996; 334:1396–7.
  13. Cleland J., Pennell D., Ray S. et al. CHRISTMAS (Carvedilol Hibernating Reversible ISchaemia Trial: MArker of Success). Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (trial): randomised controlled trial // Lancet. – 2003; 362: 14–21.
  14. Katus H., Tendera M., Mochasci P. et al. Effect of carvedilol on major clinical 14. events in patients with severe heart failure and an extremely depressed ejection fraction (abstract no. 2700) // Eur. Heart. J. – 2002; 23: 514.
  15. The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomised trial // Lancet. – 2001; 357: 1385–90.
  16. Krum H., Roecker E., Mochasci P. et al. Effects of initiating carvedilol in patients with severe heart failure: results from the COPERNICUS study // JAMA. – 2003; 289: 712–8.
  17. Yamamoto K., Origasa H, Hori Masatsugu et al. Effects of carvedilol on 17. heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF) // Eur. J. Heart Failure. – 2013; 15 (1): 110–8.
  18. Belenkov Ju.N. Remodelirovanie levogo zheludochka: kompleksnyj pod hod // Serdechnaja nedostatochnost'. – 2002; 4 (14): 161–3.
  19. Bakaev R.G. Osobennosti formirovanija, progressirovanija i rezul' taty dlitel'noj medikamentoznoj terapii hronicheskoj serdechnoj nedosta-tochnosti u bol'nyh IBS, perenesshih infarkt miokarda, i u patsientov s HOBL i hronicheskim legochnym serdtsem. Avtoref. dis. … d-ra med. nauk. M., 2010.
  20. Zhuravleva M.V. Karvedilol – effektivnoe sredstvo terapii serdech-20. noj nedostatochnosti // Farmateka. – 2004; 2: 16–26.
  21. Bellenger N., Burgess M., Ray S. et al. CHRISTMAS Study Steering 21. Committee and Investigators // Eur. Heart J. – 2000; 2: 1387–96.
  22. Skvortsov V.V., Tumarenko A.V., Skvortsova E.M. i dr. Ishemicheskaja 22. bolezn' serdtsa i stenokardija // Meditsinskaja sestra. – 2015; 7: 3–9.